Literature DB >> 25521275

Comparison of nerve growth factor-induced sensitization pattern in lumbar and tibial muscle and fascia.

Benjamin Weinkauf1,2, Saskia Deising2, Otilia Obreja2, Ulrich Hoheisel3, Siegfried Mense3, Martin Schmelz2, Roman Rukwied2.   

Abstract

INTRODUCTION: Nerve growth factor (NGF) induces profound hyperalgesia. In this study we explored patterns of NGF sensitization in muscle and fascia of distal and paraspinal sites.
METHODS: We injected 1 µg of NGF into human (n = 8) tibialis anterior and erector spinae muscles and their fasciae. The spatial extent of pressure sensitization, pressure pain threshold, and mechanical hyperalgesia (150 kPa, 10 s) was assessed at days 0.25, 1, 3, 7, 14, and 21. Chemical sensitization was explored by acidic buffer injections (pH 4, 100 µl) at days 7 and 14.
RESULTS: The mechanical hyperalgesia area was larger in tibial fascia than in muscle. Pressure pain thresholds were lower, tonic pressure pain ratings, and citrate buffer evoked pain higher in fascia than in muscle.
CONCLUSIONS: Spatial mechanical sensitization differs between muscle and fascia. Thoracolumbar fasciae appear more sensitive than tibial fasciae and may be major contributors to low back pain, but the temporal sensitization profile is similar between paraspinal and distal sites. Muscle Nerve 52: 265-272, 2015.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  TrkA; hyperalgesia; low back pain; low pH; neurotrophin

Mesh:

Substances:

Year:  2015        PMID: 25521275     DOI: 10.1002/mus.24537

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  7 in total

1.  Prevention and reversal of latent sensitization of dorsal horn neurons by glial blockers in a model of low back pain in male rats.

Authors:  Juanjuan Zhang; Siegfried Mense; Rolf-Detlef Treede; Ulrich Hoheisel
Journal:  J Neurophysiol       Date:  2017-06-14       Impact factor: 2.714

2.  Tenderness of the Skin after Chemical Stimulation of Underlying Temporal and Thoracolumbar Fasciae Reveals Somatosensory Crosstalk between Superficial and Deep Tissues.

Authors:  Walter Magerl; Emanuela Thalacker; Simon Vogel; Robert Schleip; Thomas Klein; Rolf-Detlef Treede; Andreas Schilder
Journal:  Life (Basel)       Date:  2021-04-21

3.  Spinal Mobilization Prevents NGF-Induced Trunk Mechanical Hyperalgesia and Attenuates Expression of CGRP.

Authors:  William R Reed; Joshua W Little; Carla R Lima; Robert E Sorge; Ceren Yarar-Fisher; Mualla Eraslan; Christopher P Hurt; Timothy J Ness; Jianguo G Gu; Daniel F Martins; Peng Li
Journal:  Front Neurosci       Date:  2020-04-30       Impact factor: 4.677

4.  Response To: Non-Specific Low Back Pain In Elderly And The Effects Of Myofascial Release Technique Combined With Core Stabilization Exercise: Not Just Muscles [Response To Letter].

Authors:  Gulsah Ozsoy; Nursen Ilcin; Ismail Ozsoy; Barış Gurpinar; Oznur Buyukturan; Buket Buyukturan; Caner Kararti; Senem Sas
Journal:  Clin Interv Aging       Date:  2019-11-07       Impact factor: 4.458

5.  Rat dorsal horn neurons primed by stress develop a long-lasting manifest sensitization after a short-lasting nociceptive low back input.

Authors:  Sathish Kumar Singaravelu; Ulrich Hoheisel; Siegfried Mense; Rolf-Detlef Treede
Journal:  Pain Rep       Date:  2021-03-04

Review 6.  Current Concept of Quantitative Sensory Testing and Pressure Pain Threshold in Neck/Shoulder and Low Back Pain.

Authors:  Hidenori Suzuki; Shu Tahara; Mao Mitsuda; Hironori Izumi; Satoshi Ikeda; Kazushige Seki; Norihiro Nishida; Masahiro Funaba; Yasuaki Imajo; Kiminori Yukata; Takashi Sakai
Journal:  Healthcare (Basel)       Date:  2022-08-07

7.  Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety.

Authors:  John D Markman; Robert B Bolash; Timothy E McAlindon; Alan J Kivitz; Manuel Pombo-Suarez; Seiji Ohtori; Frank W Roemer; David J Li; Lars Viktrup; Candace Bramson; Christine R West; Kenneth M Verburg
Journal:  Pain       Date:  2020-09-01       Impact factor: 7.926

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.